Pfizer and BioNTech Pause COVID-19 Vaccine Trial Due to Low Enrollment
Published on: April 1, 2026, 10:14 p.m. | Source: Devdiscourse
Pfizer and BioNTech have stopped their large U.S. COVID-19 vaccine trial in adults aged 50 to 64, citing insufficient enrollment to generate necessary data. The trial faced recruitment challenges, with over 80% of interested participants failing pre-screening due to health criteria. Moderna continues its similar study.
